Epigallocatechin-3-gallate(EGCG): Mechanisms and the Combined Applications | BenthamScience


Epigallocatechin-3-gallate(EGCG): Mechanisms and the Combined Applications

Author(s): Xuekun Song, Juan Du, Wenyuan Zhao, Zheng Guo*.

Journal Name: Combinatorial Chemistry & High Throughput Screening

Volume 20 , Issue 10 , 2017

Abstract:

Background: Epigallocatechin-3-gallate (EGCG) is an important pharmacological component in tea, and various effects, including anti-tumor, anti-inflammation, anti-aging, antiobesity, anti-diabetes, cardiovascular disease prevention and protection, immunoregulation, and neuroprotection, of this component have been confirmed. However, EGCG has been rarely used in clinical applications because of its poor stability and low bioavailability.

Objective: The work summarizes the characteristics about EGCG, describes its pharmacological mechanisms, explores the clinical availability of EGCG, and establishes a basis for EGCG preparations in clinical applications.

Conclusion: In addition to altering dosage forms or synthesizing analogs to overcome losses during absorption, inducing gauxiliary effect and enhancing chemosensitivity can be achieved by EGCG in a combined medication. The pharmacological action, pharmacology network, including mutation of signaling receptor and modulation of intracellular signaling pathway, and combination treatment strategy of EGCG are clarified and distinguished. Possible targets and combined applications based on the characteristics of EGCG are also systematically summarized. EGCG may be a candidate compound that maintains balance of the patient's disease progression and becomes suitable for clinical use in combination treatment.

Keywords: EGCG, auxiliary effect, enhancing chemosensitivity, combined medication, pharmacological action, pharmacology network.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 10
Year: 2017
Page: [872 - 885]
Pages: 14
DOI: 10.2174/1386207321666171218115850
Price: $58

Article Metrics

PDF: 23
HTML: 2
EPUB: 1
PRC: 1